Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$ODYY NEWS OUT!! This could go viral!!!
Odyssey Group International Announces Formation of Sports Advisory Board to Enhance Awareness of Traumatic Brain Injuries and Concussions
Press Release | 03/17/2021
IRVINE, Calif., March 17, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, is pleased to announce the formation of a Sports Advisory Board (SAB) to increase awareness regarding the unmet medical need for a treatment for brain injuries including concussion. The Company is in the pre-clinical phase of development of a drug compound (PRV-002) and is preparing for its first human clinical trial. The inaugural members of the SAB include notable professional athletes who have a passion to advance treatments for brain injuries:
Kurt Warner – NFL Hall of Fame, NFL MVP, Super Bowl MVP, Super Bowl Champion
Brett Favre – NFL Hall of Fame Quarterback, Super Bowl Champion, 3x consecutive MVP
Mark Rypien – 2x Super Bowl Champion, 1st Canadian quarterback to start in the NFL
David Ross – Current Manager of the Chicago Cubs, 2x World Series Champion catcher
Steve “Mooch” Mariucci – Head coach San Francisco 49er’s from 1997-2002 and Detroit Lions from 2003-2005, current member of the NFL’s Player Safety Advisory Committee.
The SAB will support Odyssey’s outreach efforts to enhance public awareness of traumatic brain injuries and concussion as well as the need for an FDA approved therapy.
Michael Redmond, CEO of Odyssey said, “We are pleased to announce the formation of our Sports Advisory Board during Brain Injury Awareness month. Each of these new members have been directly affected by traumatic brain injury and have first-hand experience of its effects on health and quality of life. Concussion is a major health issue not only in sports but also in the military and in everyday life. Our sports advisory board will play an integral role in enhancing the public’s awareness and understanding of the impacts of this common condition for which there is currently no FDA-approved drug treatment. We believe that if we successfully develop and commercialize PRV-002, we will be able to significantly improve outcomes for concussion patients.”
About Odyssey Group International, Inc.
Odyssey Group International, Inc. (OTCQB:ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.
For more information, visit: http://www.odysseygi.com
About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to close on the agreement in a timely manner, successfully complete a Phase 1 clinical trial, the economic slowdown affecting companies, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Media and Investors Contacts:
CG CAPITAL
Rich Cockrell
877.889.1972
investorrelations@cg.capital
Fun great news. Once this goes viral look out!! $ODYY
Sorry i disagree. With any biotech it's a crap shoot. But once this makes it's way through the regulatory process (and I love their chance), this will be an uplift for sure. GLTY $ODYY
$ODYY News Out!!!
Odyssey Group International, Inc. Closes Acquisition of Novel Concussion Drug
Press Release | 03/02/2021
Anticipates initiation of Phase 1 clinical trials of PRV-002 during the Second Quarter of 2021
IRVINE, CA / ACCESSWIRE / March 2, 2021 / Odyssey Group International, Inc. (OTCQB:ODYY) ("Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, is pleased to announce that it has closed the previously announced acquisition of drug candidate PRV-002, a novel neurosteroid being developed for the treatment of concussion (mild traumatic brain injury (mTBI)), from Prevacus, Inc. ("Prevacus") in an all-stock transaction. A comprehensive video of the drug, and a description of how it works is available on the Company's Youtube channel.
Concussion has become an epidemic in sports, military and elderly populations. More than 3 million sports and recreational concussions occur in the U.S. annually, and an estimated 1.5 million more go unreported. These figures do not include the significant number of concussions sustained in other high-risk incidents, including motor vehicle accidents and elderly falls. Despite the high incidence rate, there are currently no FDA-approved drugs for concussion; the market for a treatment is estimated to be over $2 billion annually.
In preclinical animal studies, nasal administration of PRV-002 has shown rapid, broad brain biodistribution and simultaneously reduced swelling, inflammation and oxidative stress with positive safety data. In addition, results from subjects treated with PRV-002 post-concussion showed positive behavioral outcomes using various testing platforms.
Dr. Jake VanLandingham, Chief Executive Officer of Prevacus, has joined Odyssey as the Company's new Vice President of Drug Development and will continue to lead the development of PRV-002. Dr. VanLandingham stated, "I am honored and excited to join Odyssey. PRV-002 has performed well in preclinical studies with promising efficacy and safety data in animal models. We will be laser-focused on the initiation of our first in-human clinical trials during the second quarter of 2021."
Michael Redmond, CEO of Odyssey added, "I am thrilled to welcome Dr. VanLandingham to the Odyssey team. His drug development ability and expertise will be invaluable as we develop PRV-002 and for future projects. Concussion is a serious health issues and we believe that by developing PRV-002 we can significantly improve patient outcomes."
About Odyssey Group International, Inc.
Odyssey Group International, Inc. (OTCQB:ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.
For more information, visit: http://www.odysseygi.com
About Prevacus, Inc.
Prevacus, Inc. is a biopharmaceutical company developing drug candidates with the potential to advance treatment in the fields of traumatic brain injury and other neurological disorders. The Company's first two development candidates (PRV-002 and PreVPro) represent breakthrough strategy for treating concussion working at the molecular level to simultaneously reduce inflammation, swelling, impaired cerebral blood flow and oxidative stress.
For more information visit: http://www.prevacus.com.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to close on the agreement in a timely manner, successfully complete a Phase 1 clinical trial, the economic slowdown affecting companies, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Media and Investors Contacts:
CG CAPITAL
Rich Cockrell
877.889.1972
investorrelations@cg.capital
$ODYY NEWS OUT!!!
Odyssey Group International, Inc. Closes Acquisition of Novel Concussion Drug
Press Release | 03/02/2021
Anticipates initiation of Phase 1 clinical trials of PRV-002 during the Second Quarter of 2021
IRVINE, CA / ACCESSWIRE / March 2, 2021 / Odyssey Group International, Inc. (OTCQB:ODYY) ("Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, is pleased to announce that it has closed the previously announced acquisition of drug candidate PRV-002, a novel neurosteroid being developed for the treatment of concussion (mild traumatic brain injury (mTBI)), from Prevacus, Inc. ("Prevacus") in an all-stock transaction. A comprehensive video of the drug, and a description of how it works is available on the Company's Youtube channel.
Concussion has become an epidemic in sports, military and elderly populations. More than 3 million sports and recreational concussions occur in the U.S. annually, and an estimated 1.5 million more go unreported. These figures do not include the significant number of concussions sustained in other high-risk incidents, including motor vehicle accidents and elderly falls. Despite the high incidence rate, there are currently no FDA-approved drugs for concussion; the market for a treatment is estimated to be over $2 billion annually.
In preclinical animal studies, nasal administration of PRV-002 has shown rapid, broad brain biodistribution and simultaneously reduced swelling, inflammation and oxidative stress with positive safety data. In addition, results from subjects treated with PRV-002 post-concussion showed positive behavioral outcomes using various testing platforms.
Dr. Jake VanLandingham, Chief Executive Officer of Prevacus, has joined Odyssey as the Company's new Vice President of Drug Development and will continue to lead the development of PRV-002. Dr. VanLandingham stated, "I am honored and excited to join Odyssey. PRV-002 has performed well in preclinical studies with promising efficacy and safety data in animal models. We will be laser-focused on the initiation of our first in-human clinical trials during the second quarter of 2021."
Michael Redmond, CEO of Odyssey added, "I am thrilled to welcome Dr. VanLandingham to the Odyssey team. His drug development ability and expertise will be invaluable as we develop PRV-002 and for future projects. Concussion is a serious health issues and we believe that by developing PRV-002 we can significantly improve patient outcomes."
About Odyssey Group International, Inc.
Odyssey Group International, Inc. (OTCQB:ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.
For more information, visit: http://www.odysseygi.com
About Prevacus, Inc.
Prevacus, Inc. is a biopharmaceutical company developing drug candidates with the potential to advance treatment in the fields of traumatic brain injury and other neurological disorders. The Company's first two development candidates (PRV-002 and PreVPro) represent breakthrough strategy for treating concussion working at the molecular level to simultaneously reduce inflammation, swelling, impaired cerebral blood flow and oxidative stress.
For more information visit: http://www.prevacus.com.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to close on the agreement in a timely manner, successfully complete a Phase 1 clinical trial, the economic slowdown affecting companies, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Media and Investors Contacts:
CG CAPITAL
Rich Cockrell
877.889.1972
investorrelations@cg.capital
SOURCE: Odyssey Group International Inc.
View source version on accesswire.com:
https://www.accesswire.com/632846/Odyssey-Group-International-Inc-Closes-Acquisition-of-Novel-Concussion-Drug
Great news Fun!!! $ODYY
Doesn't seem so. Those late day sales indicate he's still active. JMHO GLTY
Doesn't seem that the seller is gone. hmmmmmmmm $TQLB
BBW i would think it's around 500k. Very thin on the offer and recent trading seems to indicate. GLTY and thanks for the info $TQLB
$TQLB Torque Announces Fully Executed LOI to Acquire a Market Leader in Keto Market https://finance.yahoo.com/news/torque-announces-fully-executed-loi-130000047.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr
$TQLB Torque Announces Fully Executed LOI to Acquire a Market Leader in Keto Market https://finance.yahoo.com/news/torque-announces-fully-executed-loi-130000047.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr
$TQLB .50 low floater and recent news!!!
Sure is Fit. Great news $TQLB
$ODYY NEWS OUT!!!
Odyssey Group International/Prevacus, Inc. Reports Brain Bio-Distribution Findings of PRV-002
Press Release | 02/17/2021
Pre-clinical data for PRV-002, a nasally delivered drug in development for treating concussion, highlight rapid brain bioavailability
IRVINE, CA / ACCESSWIRE / February 17, 2021 / Odyssey Group International, Inc. (OTCQB:ODYY) ("Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, and Prevacus Inc., are pleased to report the results of pre-clinical studies related to brain biodistribution of PRV-002 (Prevasol), a novel compound in development for the treatment of concussion.
In this study, PRV-002, a neurosteroid, was formulated in its native form and as a nanoparticle. Pre-clinical animal studies of PRV-002 have shown rapid absorption in the brain with biodistribution across the entire brain when administered nasally.
"We are pleased to see such a significant level of the compound reach the brain over the 8-hour period of nasal administration. These data confirm our hypothesis that the administration of nasal nanoparticles improves brain bioavailability. PRV-002 was most concentrated in the frontal lobe, which makes perfect sense given its direct connection with the olfactory nerves. Nasal application is ideal for quick, on-the-field administration and conditions of acute brain inflammation where immediate treatment is critical." said Dr. Jake VanLandingham, Chief Executive Officer of Prevacus.
In this study, conducted by Inotiv for Prevacus, both forms of PRV-002 were nasally administered to subjects three times: one initial dose and two subsequent doses given in 4-hour intervals. Brain tissue was analyzed at 8-hours post-initial nasal application. When formulated as a nanoparticle, approximately 40% more PRV-002 was found in all brain cortices, including the cerebellum, at 8-hours. These results were almost identical when measured in cerebrospinal fluid. When allometrically scaled, the dosing concentrations in this study represent the lowest dose intended for use in the planned Phase 1 human trials.
Michael Redmond, CEO of Odyssey added, "concussion is a serious health issue in sports, the military and in elderly populations which currently has no FDA approved drug treatment. These animal data support PRV-002's brain bioavailability following brain trauma. We are eager to close our transaction and contribute to the drug development program."
Odyssey previously entered into a definitive agreement with Prevacus to acquire the Active Pharmaceutical Ingredient PRV-002 (Prevasol) to treat traumatic brain injury on January 11, 2021. The definitive agreement has been signed, and the transaction is expected to close by the end of February 2021. The transaction is conditional on Prevacus shareholder approval and other customary closing conditions.
About Odyssey Group International, Inc.
Odyssey Group International, Inc. (OTCQB:ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.
For more information, visit: http://www.odysseygi.com
About Prevacus, Inc.
Prevacus, Inc. is a biopharmaceutical company developing drug candidates with the potential to advance treatment in the fields of traumatic brain injury and other neurological disorders. The Company's first two development candidates (PRV-002 and PreVPro) represent breakthrough strategy for treating concussion working at the molecular level to simultaneously reduce inflammation, swelling, impaired cerebral blood flow and oxidative stress.
For more information visit: http://www.prevacus.com.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to close on the agreement in a timely manner, successfully complete a Phase 1 clinical trial, the economic slowdown affecting companies, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Media and Investors Contacts:
CG CAPITAL
Rich Cockrell
877.889.1972
investorrelations@cg.capital
$ODYY NEWS OUT!!
Odyssey Group International/Prevacus, Inc. Reports Brain Bio-Distribution Findings of PRV-002
Press Release | 02/17/2021
Pre-clinical data for PRV-002, a nasally delivered drug in development for treating concussion, highlight rapid brain bioavailability
IRVINE, CA / ACCESSWIRE / February 17, 2021 / Odyssey Group International, Inc. (OTCQB:ODYY) ("Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, and Prevacus Inc., are pleased to report the results of pre-clinical studies related to brain biodistribution of PRV-002 (Prevasol), a novel compound in development for the treatment of concussion.
In this study, PRV-002, a neurosteroid, was formulated in its native form and as a nanoparticle. Pre-clinical animal studies of PRV-002 have shown rapid absorption in the brain with biodistribution across the entire brain when administered nasally.
"We are pleased to see such a significant level of the compound reach the brain over the 8-hour period of nasal administration. These data confirm our hypothesis that the administration of nasal nanoparticles improves brain bioavailability. PRV-002 was most concentrated in the frontal lobe, which makes perfect sense given its direct connection with the olfactory nerves. Nasal application is ideal for quick, on-the-field administration and conditions of acute brain inflammation where immediate treatment is critical." said Dr. Jake VanLandingham, Chief Executive Officer of Prevacus.
In this study, conducted by Inotiv for Prevacus, both forms of PRV-002 were nasally administered to subjects three times: one initial dose and two subsequent doses given in 4-hour intervals. Brain tissue was analyzed at 8-hours post-initial nasal application. When formulated as a nanoparticle, approximately 40% more PRV-002 was found in all brain cortices, including the cerebellum, at 8-hours. These results were almost identical when measured in cerebrospinal fluid. When allometrically scaled, the dosing concentrations in this study represent the lowest dose intended for use in the planned Phase 1 human trials.
Michael Redmond, CEO of Odyssey added, "concussion is a serious health issue in sports, the military and in elderly populations which currently has no FDA approved drug treatment. These animal data support PRV-002's brain bioavailability following brain trauma. We are eager to close our transaction and contribute to the drug development program."
Odyssey previously entered into a definitive agreement with Prevacus to acquire the Active Pharmaceutical Ingredient PRV-002 (Prevasol) to treat traumatic brain injury on January 11, 2021. The definitive agreement has been signed, and the transaction is expected to close by the end of February 2021. The transaction is conditional on Prevacus shareholder approval and other customary closing conditions.
About Odyssey Group International, Inc.
Odyssey Group International, Inc. (OTCQB:ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.
For more information, visit: http://www.odysseygi.com
About Prevacus, Inc.
Prevacus, Inc. is a biopharmaceutical company developing drug candidates with the potential to advance treatment in the fields of traumatic brain injury and other neurological disorders. The Company's first two development candidates (PRV-002 and PreVPro) represent breakthrough strategy for treating concussion working at the molecular level to simultaneously reduce inflammation, swelling, impaired cerebral blood flow and oxidative stress.
For more information visit: http://www.prevacus.com.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to close on the agreement in a timely manner, successfully complete a Phase 1 clinical trial, the economic slowdown affecting companies, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Media and Investors Contacts:
CG CAPITAL
Rich Cockrell
877.889.1972
investorrelations@cg.capital
More positive news Fun. $ODYY
Hopefully we reached our bottom. Next few hours will tell though. GLTY
Thanks for the info Cabo. I've been a believer since it was .17 . $ODYY is a game changer !!!!!
$ODYY NEXT STOP $2.00!!!!
Fun $ODYY next stop $2.00.
$ODYY ANOTHER BANNER DAY!!!!
FUN $ODYY ROCKING PRE-MARKET
$ODYY ROCKING PRE-MARKET!!!!!
$odyy was on Fox Business News tonight!!!
$ODYY NEXT STOP NASDAQ!!!!!!!!
Fun on track for the Nasdaq Listing!!!!! $ODYY WEEEEEEEEEEEEEEEEEEEEEEEEEEEE
$ODYY Featured on Fox & Friends this past weekend!! Ready for next stage lift-off!!!!
Along with many others!! I think we push towards $1.00. JMHO GLTY $ODYY!!!
Sorry Fun. You're a little more tech advanced than myself. This is going to fly!!!!$ODYY!!!!!
$ODYY on Fox & Friends with Kurt Warner this morning at 9:15!!!!
$ODYY on Fox & Friends with Kurt Warner @ 9:15 this morning!!!!
ODYY ON CHEDDAR TV NOW WITH BRETT FAVRE!!!!!
$ODYY ON CHEDDAR TV WITH BRETT FAVRE
Thanks let us know what you find!! $ODYY!!!!
$ODYY continues to climb with Concussion drug trials!!!!
Due to the wide spread issues surrounding "concussions", i would think the FDA would put this on the fast track, especially with youth sports coming back online. JMHO goooo $ODYY!!!!!
$ODYY accumulation continues...